Clinical trials: Ampullary Adenocarcinoma
Pancreas Cancer With Hepatic Metastase, Pancreas Adenocarcinoma
Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma
The goal of this observational study is to evaluate whether hepatic artery infusion pump (HAIP) chemotherapy can improve outcomes in patients with pancreatic or duodenal adenocarcinoma who have isolated or liver-dominant…
- Conditions
- Pancreas Cancer With Hepatic Metastase, Pancreas Adenocarcinoma, Duodenal Cancer, Duodenal Adenocarcinoma
- Trial name
- NCT07845617
- Testing
- Hepatic Artery Infusion Pump (HAIP), Floxuridine (FUDR)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- AdventHealth
Pancreas Cancer, Periampullary Cancer
Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
Adjuvant chemotherapy after surgery significantly improved the survival of pancreatic cancer (PC) patients, but there is a problem that only about 50% of patients start adjuvant chemotherapy after pancreatectomy.
- Conditions
- Pancreas Cancer, Periampullary Cancer, Periampullary Carcinoma Resectable, Pancreatic Cancer Resectable
- Trial name
- NCT07081360
- Testing
- Neoadjuvant chemotherapy, Upfront Surgery Group
- Where
- Egypt
- Volunteers
- 262 people
- Sponsor
- Minia University
Foregut Adenocarcinoma, Esophageal Adenocarcinoma
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of…
- Conditions
- Foregut Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- OLIGOMETS (NCT07282912)
- Testing
- Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Yale University
Ampullary Carcinoma, Duodenal Adenocarcinoma
Modified Single-Incision Plus One-Port Versus Conventional Five-Port Laparoscopic Pancreaticoduodenectomy for Nonpancreatic Periampullary Adenocarcinomas
This multicenter, randomized, controlled, non-inferiority trial will compare modified single-incision plus one-port laparoscopic pancreaticoduodenectomy (mSILPD+1) with conventional five-port laparoscopic pancreaticoduodenectomy…
- Conditions
- Ampullary Carcinoma, Duodenal Adenocarcinoma, Distal Cholangiocarcinoma
- Trial name
- NCT07744087
- Testing
- Modified Single Incision plus one-port Laparoscopic Pancreaticoduodenectomy, Conventional Laparoscopic Pancreaticoduodenectomy
- Where
- 4 sites in China
- Volunteers
- 232 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Pancreatic Ductal Adenocarcinoma, Ampullary Carcinoma
Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy
This is a monocentric, prospective, randomized controlled trial comparing the safety and efficacy of laparoscopic pancreaticoduodenectomy (LPD) versus open pancreaticoduodenectomy (OPD).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Ampullary Carcinoma, Distal Cholangiocarcinoma, Duodenal Adenocarcinoma
- Trial name
- NCT07328607
- Testing
- Open Pancreaticoduodenectomy, Laparoscopic Pancreaticoduodenectomy
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Minia University
Pancreatic Adenocarcinoma, Pancreatic Cysts
Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors
This multicenter randomized trial aims to primarily assess and compare the functional recovery of patients who undergo open versus robotic pancreaticoduodenectomy for benign and malignant lesions of the head of the pancreas.
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Cysts, Pancreatic Endocrine Tumors, Chronic Pancreatitis
- Trial name
- PORTAL (NCT04400357)
- Testing
- Robotic pancreaticoduodenectomy, Open pancreaticoduodenectomy
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Ruijin Hospital
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Duodenum
Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula
Curative management of locally resectable invasive adenocarcinomas located in the cephalic region of the pancreas (pancreas, duodenum and ampulla of Vater) requires a pancreaticoduodenectomy followed by adjuvant chemotherapy.
- Conditions
- Adenocarcinoma of the Pancreas, Adenocarcinoma of the Duodenum, Ampullary Adenocarcinoma
- Trial name
- TPIAT-01 (NCT05116072)
- Testing
- total pancreatectomy, intraportal islet autotransplantation
- Where
- France
- Volunteers
- 36 people
- Sponsor
- University Hospital, Lille
Ampullary Adenocarcinoma
PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma
Ampullary adenocarcinoma (AMPAC) is a rare cancer (0.2% of digestive cancers) affecting the ampulla of Vater. The only curative treatment is surgery, but around 4% of patients recur within 2 years of surgical resection.
- Trial name
- AMPIRINOX (NCT06813976)
- Testing
- mFOLFORINOX, Capecitabine or gemcitabine, Quality of life questionnaires: QLQ-C30 and PAN26
- Where
- France
- Volunteers
- 294 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Pancreatic Cancer, Ampullary Cancer
Recurrence After Whipple's (RAW) Study
Pancreatic head malignancies are aggressive cancers that are often inoperable when they are diagnosed. In the ~20% of patients who are diagnosed when the disease is still operable, surgery is the only treatment that can provide a…
- Conditions
- Pancreatic Cancer, Ampullary Cancer, Bile Duct Cancer, Cholangiocarcinoma, Extrahepatic
- Trial name
- NCT04596865
- Testing
- Pancreaticoduodenectomy
- Where
- 29 sites in Australia, Austria and 6 more
- Volunteers
- 1,484 people
- Sponsor
- University Hospital Plymouth NHS Trust
Ampullary Adenocarcinoma
The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.
Ampullary adenocarcinoma (AAC) is a rare gastrointestinal cancer with varying survival rates, particularly the aggressive pancreatobiliary (PB) subtype.
- Trial name
- ADAPTA (NCT06068023)
- Testing
- Folfirinox, Capox
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Poliambulanza Istituto Ospedaliero
Ampullary Adenocarcinoma
Survival and Description of Care for Patients With Degenerate Vaterian Ampulloma
A Vater's ampulloma is a rare digestive tumour which accounts for under 1% of all digestive tumours. The only curative treatment is complete excision (surgical or endoscopic) of the lesions which is possible in 80% of cases …
- Trial name
- AMPULLOMA (NCT03800212)
- Testing
- treatment for ampullary adenocarcinoma
- Where
- 36 sites in France
- Volunteers
- 402 people
- Sponsor
- Federation Francophone de Cancerologie Digestive